NASDAQ:ANNX Annexon (ANNX) Stock Price, News & Analysis $5.75 -0.07 (-1.20%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$5.54▼$6.0050-Day Range$4.49▼$6.4652-Week Range$1.57▼$8.40Volume612,633 shsAverage Volume1.94 million shsMarket Capitalization$531.37 millionP/E RatioN/ADividend YieldN/APrice Target$15.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Annexon alerts: Email Address Annexon MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside174.8% Upside$15.80 Price TargetShort InterestBearish7.87% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.17Based on 9 Articles This WeekInsider TradingSelling Shares$75,122 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.97) to ($1.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.00 out of 5 starsMedical Sector537th out of 910 stocksPharmaceutical Preparations Industry247th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingAnnexon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnnexon has only been the subject of 2 research reports in the past 90 days.Read more about Annexon's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.87% of the outstanding shares of Annexon have been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Annexon has recently increased by 1.82%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAnnexon does not currently pay a dividend.Dividend GrowthAnnexon does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANNX. Previous Next 2.9 News and Social Media Coverage News SentimentAnnexon has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Annexon this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for ANNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Annexon to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Annexon insiders have sold 40.40% more of their company's stock than they have bought. Specifically, they have bought $53,504.00 in company stock and sold $75,122.00 in company stock.Percentage Held by Insiders12.67% of the stock of Annexon is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Annexon's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Annexon are expected to decrease in the coming year, from ($0.97) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annexon is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annexon is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnnexon has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Annexon's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm Press Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are in this announcement. About Annexon Stock (NASDAQ:ANNX)Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Read More ANNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANNX Stock News HeadlinesSeptember 7 at 9:25 AM | insidertrades.comAnnexon, Inc. (NASDAQ:ANNX) EVP Sells 5,500 SharesSeptember 5 at 7:27 AM | insidertrades.comAnnexon, Inc. (NASDAQ:ANNX) Director Buys $17,536.00 in StockSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 1, 2024 | insidertrades.comTed Yednock Sells 5,500 Shares of Annexon, Inc. (NASDAQ:ANNX) StockSeptember 1, 2024 | americanbankingnews.comAnnexon (NASDAQ:ANNX) Trading Down 2.5% Following Insider SellingAugust 29, 2024 | finance.yahoo.comAnnexon Biosciences to Participate in Upcoming September Investor ConferencesAugust 28, 2024 | americanbankingnews.comAnnexon, Inc. (NASDAQ:ANNX) Receives $15.80 Consensus Target Price from AnalystsAugust 16, 2024 | globenewswire.comAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)September 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Annexon Biosciences Amid Promising Clinical Trial ResultsAugust 14, 2024 | markets.businessinsider.comAnnexon Biosciences: Accelerated Timelines and Financial Stability Bolster Buy RatingAugust 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Annexon Biosciences Amid Pivotal Clinical Advances and Strong Sales ForecastAugust 12, 2024 | markets.businessinsider.comAnnexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated MilestonesAugust 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Green Thumb Industries (OtherGTBIF) and Annexon Biosciences (ANNX)August 5, 2024 | markets.businessinsider.comAnnexon Provides Update on ARCHER II Global Registrational Program in Geographic AtrophyAugust 3, 2024 | finance.yahoo.comAnnexon Insider Ups Holding During YearJuly 16, 2024 | globenewswire.comAnnexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)July 11, 2024 | globenewswire.comAnnexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific MeetingSee More Headlines Receive ANNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANNX CUSIPN/A CIK1528115 Webwww.annexonbio.com Phone650-822-5500Fax650-636-9773Employees60Year FoundedN/APrice Target and Rating Average Stock Price Target$15.80 High Stock Price Target$30.00 Low Stock Price Target$10.00 Potential Upside/Downside+174.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-134,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.68% Return on Assets-38.02% Debt Debt-to-Equity RatioN/A Current Ratio21.81 Quick Ratio21.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.42 per share Price / Book1.68Miscellaneous Outstanding Shares92,413,000Free Float80,704,000Market Cap$531.37 million OptionableOptionable Beta1.28 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Douglas Love Esq. (Age 56)J.D., CEO, President & Director Comp: $980.12kDr. Dean R. Artis Ph.D. (Age 63)Chief Scientific Officer & Executive VP Comp: $797.38kDr. Ted Yednock Ph.D. (Age 66)Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board Comp: $697.76kMs. Jennifer Lew (Age 51)Executive VP, CFO & Corporate Secretary Comp: $624.2kMr. Michael Overdorf M.B.A. (Age 53)Executive VP & Chief Business Officer Comp: $580.47kHenk-Andre Kroon M.D.Senior Vice President of Translational MedicineDr. Jamie Dananberg M.D. (Age 66)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsTheravance BiopharmaNASDAQ:TBPHPliant TherapeuticsNASDAQ:PLRXEnanta PharmaceuticalsNASDAQ:ENTAVerona PharmaNASDAQ:VRNABausch Health CompaniesNYSE:BHCView All CompetitorsInsiders & InstitutionsTed YednockSold 5,500 sharesTotal: $31,020.00 ($5.64/share)William H CarsonBought 3,200 shares on 9/3/2024Total: $17,536.00 ($5.48/share)Maven Securities LTDBought 34,707 shares on 8/29/2024Ownership: 0.038%Ted YednockSold 5,500 sharesTotal: $32,725.00 ($5.95/share)Point72 Europe London LLPBought 234,592 shares on 8/15/2024Ownership: 0.254%View All Insider TransactionsView All Institutional Transactions ANNX Stock Analysis - Frequently Asked Questions How have ANNX shares performed this year? Annexon's stock was trading at $4.54 at the beginning of 2024. Since then, ANNX stock has increased by 26.7% and is now trading at $5.75. View the best growth stocks for 2024 here. How were Annexon's earnings last quarter? Annexon, Inc. (NASDAQ:ANNX) posted its earnings results on Monday, August, 12th. The company reported ($0.23) EPS for the quarter, hitting analysts' consensus estimates of ($0.23). When did Annexon IPO? Annexon (ANNX) raised $150 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen served as the underwriters for the IPO. Who are Annexon's major shareholders? Top institutional shareholders of Annexon include Point72 Asset Management L.P. (6.48%), Candriam S.C.A. (2.22%), Marshall Wace LLP (1.83%) and Massachusetts Financial Services Co. MA (1.15%). Insiders that own company stock include Bain Capital Life Sciences Inv, Douglas Love, Michael Overdorf, Jennifer Lew, William H Carson and Ted Yednock. View institutional ownership trends. How do I buy shares of Annexon? Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Annexon own? Based on aggregate information from My MarketBeat watchlists, some other companies that Annexon investors own include Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Johnson & Johnson (JNJ) and RTX (RTX). This page (NASDAQ:ANNX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANNX Stock Alerts